Article

Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine

2022-07-18

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Introduction</h4> Third doses of COVID-19 vaccination provide an important boost to immunity, reducing the risk of symptomatic infection and the risk of severe disease. Third doses have been particularly important for improving protection against variants. However, waning of clinical protection particularly against Omicron has been noted after receipt of third doses. <h4>Methods</h4> We admin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 14547b53-d7b1-5d6d-8d6e-1a2039fae4aa
DOI: 10.1101/2022.07.18.22277741

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccineDOI 10.1101/2022.07.18.22277741Read

Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-upSemantic proximity Read

Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescentsSemantic proximity Read

Boosting of Serum Neutralizing Activity Against the Omicron Variant Among Recovered COVID-19 Patients by BNT162b2 and Coronavac VaccinesSemantic proximity Read

Immune responses of the third dose of AZD1222 vaccine or BNT162b2 mRNA vaccine after two doses of CoronaVac vaccines against Delta and Omicron variantsSemantic proximity Read

BA.2 evasion of vaccine induced binding and functional non-neutralizing antibodiesSemantic proximity Read

Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster doseSemantic proximity Read

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adultsSemantic proximity Read

Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster doseSemantic proximity Read

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19Semantic proximity Read

Extended interval BNT162b2 vaccination enhances peak antibody generation in older peopleSemantic proximity Read

Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK)Semantic proximity Read

Functional and quantitative evaluation of BNT162b2 SARS-CoV-2 vaccine-induced immunitySemantic proximity Read